Once-a-day pill wipes out pancreatic cancer in some patients
Daily pill eradicates pancreatic cancer in trial patients

A once-a-day pill has completely eradicated advanced pancreatic cancer in some patients when combined with chemotherapy, according to a clinical trial. The drug, daraxonrasib, wiped out the disease in one in 12 patients, a result described by the lead medic as the ‘closest’ thing to a ‘cure’.

Trial results show high response rates

In the study, presented at the European Organisation for Research and Treatment of Cancer in Barcelona, tumours shrank or disappeared in 60.7% of patients given daraxonrasib and chemotherapy. This included complete responses in 8.2% of patients over a typical follow-up of 18 months, meaning their tumours were no longer detectable.

Overall, tumours stopped growing in 90.2% of all 61 patients studied over a typical period of 18 months. One year after treatment, 76.6% of patients were still alive, compared to around 40% to 45% when given chemotherapy alone. It took 12.8 months on average for tumours to return or start growing again across the whole patient group.

How the drug works

Daraxonrasib works by locking onto the mutated KRAS gene, found in more than nine in 10 pancreatic tumours, which continuously signals cancer cells to grow. By shutting this off, the drug can prevent tumours from spreading.

In May, the drug was found to almost double survival time for patients with aggressive and advanced pancreatic cancer compared to chemo alone. The pill also caused fewer side effects, with fewer than 5% of patients discontinuing treatment, which is regarded as low.

Experts react to the findings

Dr Wungki Park, oncologist at Memorial Sloan Kettering Cancer Centre in New York, who presented the findings, told the Press Association he had never seen such responses, calling it ‘a massive, massive breakthrough’. He said: ‘In about one in 12 patients, it (the cancer) completely disappeared. And then with such a long follow-up, this is real. We’ve never seen such a thing.’

Asked if the one in 12 patients whose tumours could not be seen were regarded as cured, he said: ‘This is the closest to cure. This is almost at the discovery level, we have never seen 8% complete response in metastatic pancreatic cancer, you don’t see that… The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.’

He said longer-term survival data would come as the trial progressed, but there is ‘some survival signal here, which is very strong’, with 76.6% of patients alive after one year. Dr Park noted that cancer frequently develops resistance to drug treatment but ‘we’re delaying that as much as possible’ through the new combined treatment.

Next steps and calls for investment

Dr Madina Kara, head of research at Pancreatic Cancer UK, said: ‘Half of people with pancreatic cancer die within three months of diagnosis and their loved ones would give anything to spend more precious time with them. This is a small, initial study, however these encouraging results now show that daraxonrasib and chemotherapy can be effective when used in combination.’

She said the team was excited for the larger clinical trial, adding: ‘These findings are part of a growing body of evidence that offers real hope to people with advanced pancreatic cancer.’ She added: ‘The UK Government must ensure we build on the momentum we are seeing by increasing investment into pancreatic research and clinical trials, so that more patients can take part in studies that could improve outcomes. It must also ensure there is a rapid pathway to deliver any game-changing new treatments to patients across the UK as soon as they are proven to work.’

More than 11,000 people are diagnosed with pancreatic cancer each year in the UK and more than 10,000 die from it, usually within a few months. Cancer Research UK chief executive Michelle Mitchell said: ‘This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers. More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low. Further research is needed to look at how this drug could be used alongside other therapies to give patients the best chance of beating the disease.’